GSK completes Novartis vaccines purchase; Galena announces positive PhIIb cancer vax results;

> GlaxoSmithKline ($GSK) completed its acquisition of Novartis' ($NVS) vaccine business. Story

> Galena Biopharma announced positive Phase IIa results of its GALE-301 immunotherapy in preventing the recurrence of ovarian and endometrial cancers. Galena also identified an optimal dose. Statement

> Aduro ($ADRO), through a $32 million purchase of Dutch biotech BioNovion, added an in-house preclinical pipeline of antibodies and checkpoint inhibitors. Report

> Researchers at the University of Rochester Medical Center received $3.1 million from the NIH to look for new ways to develop an HIV vaccine. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.